ArticleBlood cancer journal2022
Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Identification of new overlapping and disease-specific genetic risk factors for rheumatoid arthritis and radiographic axial spondyloarthritis: a meta-analysis of three large European populations and functional characterization.Frontiers in immunology · 2026Pooled it
- Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.Blood advances · 2025Pooled it
- Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression?International journal of molecular sciences · 2023Pooled it
- In-silico identification of genetic variants associated with chronic lymphocytic leukemia for diagnostic and therapeutic applications.Scientific reports · 2026Article
- Comprehensive analysis of the potential effect and mechanism of pyroptosis-related genes in treatment-related myeloid tumors.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Paloma García-Martín *Hospital Campus de la Salud, PTS Granada, Granada, Spain.
Ana Moñiz Díez *Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain.
José Manuel Sánchez Maldonado *Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain.
Antonio José Cabrera SerranoGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain.
Rob Ter HorstDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Yolanda BenaventeCatalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
Stefano LandiDepartment of Biology, University of Pisa, Pisa, Italy.ORCID 0000-0001-8364-6357
Angelica MacaudaGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Alyssa Clay-GilmourDepartment of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Greenville, SC, USA.
Francisca Hernández-MohedoHematology department, Virgen de las Nieves University Hospital, Granada, Spain.
Yasmeen NiaziDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Pedro González-SierraHematology department, Virgen de las Nieves University Hospital, Granada, Spain.ORCID 0000-0002-6492-1728
Blanca EspinetMolecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain.ORCID 0000-0002-4294-8145
Juan José Rodríguez-SevillaHematology Department, Hospital del Mar, Barcelona, Spain.
Rossana MaffeiDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, Modena, Italy.ORCID 0000-0002-3518-2006
Gonzalo BlancoMolecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain.ORCID 0000-0001-6557-3764
Matteo GiaccheriniDepartment of Biology, University of Pisa, Pisa, Italy.
Anna PuiggrosMolecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain.
James CerhanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.ORCID 0000-0002-7482-178X
Roberto MarascaDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, Modena, Italy.ORCID 0000-0002-6431-6878
Marisa Cañadas-GarreGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain.ORCID 0000-0003-1103-5658
Miguel Ángel López-NevotImmunology Department, Virgen de las Nieves University Hospital, Granada, Spain.
Tzu Chen-LiangHematology Department, Morales Meseguer University Hospital, Murcia, Spain.ORCID 0000-0001-5969-8640
Hauke ThomsenProtaGene CGT GmbH, Heidelberg, Germany.ORCID 0000-0001-5951-3116
Irene GámezHematology Department, Morales Meseguer University Hospital, Murcia, Spain.
Víctor MorenoCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.ORCID 0000-0002-2818-5487
Rafael Marcos-GrageraCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
María García-ÁlvarezDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Javier LlorcaCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Andrés JerezHematology Department, Morales Meseguer University Hospital, Murcia, Spain.
Sonja BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Aleksandra ButrymMedical University of Wrocław, Wrocław, Poland.
Aaron D NormanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Delphine CasabonneCatalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
Mario LuppiDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, Modena, Italy.
Susan L SlagerDivision of Computational Genomics, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5173-4712
Kari HemminkiDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Yang LiDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Miguel AlcocebaJosep Carreras Leukemia Research Institute, Girona, Spain.ORCID 0000-0002-3819-4846
Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4261-4583
Silvia de SanjoséCatalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain.
Asta FörstiDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Mihai G NeteaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-2421-6052
Manuel JuradoGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain.
Juan SainzGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain. juan.sainz@genyo.es.ORCID 0000-0002-9355-2423
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3MNCI NIH HHS P30 CA015083
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansPolymorphism, Single Nucleotide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.